<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881904</url>
  </required_header>
  <id_info>
    <org_study_id>OCP-AntagonistPCOS</org_study_id>
    <nct_id>NCT03881904</nct_id>
  </id_info>
  <brief_title>OCP Pretreatment in PCOS Patients Undergoing ICSI Using Antagonist Protocol</brief_title>
  <official_title>Oral Contraceptive Pill Pretreatment in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Using the Gonadotrophin Releasing Hormone Antagonist Protocol (A Randomized Controlled Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      373 women with PCOS undergoing a trial of IVF/ICSI will receive OCP from day 2 of the&#xD;
      preceding cycle for 21 days followed by GnRH antagonist COH.&#xD;
&#xD;
      Another 373 women with PCOS undergoing a trial of IVF/ICSI will start GnRH antagonist COH&#xD;
      directly without OCP pretreatment.&#xD;
&#xD;
      Both groups will be followed up for effect on ongoing pregnancy rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 740 women with polycystic ovary syndrome undergoing IVF/ICSI cycle&#xD;
      using flexible antagonist protocol.&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      Patients fulfilling the inclusion criteria will be randomized to two groups.&#xD;
&#xD;
      Study Group:&#xD;
&#xD;
      This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will&#xD;
      receive OCP from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.&#xD;
&#xD;
      Control Group:&#xD;
&#xD;
      This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will&#xD;
      start GnRH antagonist COH directly without OCP pretreatment.&#xD;
&#xD;
      Random allocation sequence generation:&#xD;
&#xD;
      A computer generated list via MedCalc ® Software, version 13.2.2 will be used, assigning each&#xD;
      participant number to either study groups.&#xD;
&#xD;
      Allocation Concealment:&#xD;
&#xD;
      Assignment will be done by sequentially numbered, otherwise identical, sealed envelopes&#xD;
      (SNOSE), each containing a 2-inch by 2-inch paper with a written code designating the&#xD;
      assigned group. These papers will be placed in a folded sheet of aluminum foil fitted inside&#xD;
      the envelope. Effort will be taken to assure absence of any detectable differences in size or&#xD;
      weight between intervention and control envelopes. Envelopes will be chosen to be opaque and&#xD;
      lined inside with carbon paper. Envelopes will be opened sequentially only after writing the&#xD;
      subject's tracking information on the envelope so that the carbon paper served as an audit&#xD;
      trail.&#xD;
&#xD;
      IVF/ICSI cycle will be done using flexible anatgonist protocol in both groups.&#xD;
&#xD;
      Primary outcome will be ongoing pregnancy rate.&#xD;
&#xD;
      Secondary outcomes will be biochemical and clinical pregnancy rates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>20 gestational weeks</time_frame>
    <description>Number of pregnancies completing ≥20 weeks gestational age expressed per 100 embryo transfer cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chemical pregnancy rate</measure>
    <time_frame>6 gestational weeks</time_frame>
    <description>Number of biochemical pregnancies (evidenced by positive pregnancy test in serum or urine without ultrasound evidence of a gestational sac) expressed per 100 embryo transfer cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>6 gestational weeks</time_frame>
    <description>Number of clinical pregnancies (evidenced by ultrasound visualization of a gestational sac and embryonic pole with heartbeat) expressed per 100 embryo transfer cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>38 gestational weeks</time_frame>
    <description>The number of deliveries (&gt; 28 weeks GA) that resulted in a live born neonate, expressed per 100 embryo transfers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">740</enrollment>
  <condition>Subfertility, Female</condition>
  <arm_group>
    <arm_group_label>OCP Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.075mg gestodene/0.03mg ethinylestradiol</intervention_name>
    <description>OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.</description>
    <arm_group_label>OCP Group</arm_group_label>
    <other_name>Gynera®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-39 years of age.&#xD;
&#xD;
          2. BMI 18-29 Kg/m2&#xD;
&#xD;
          3. Polycystic ovary syndrome, diagnosed - according to the revised 2003 consensus on&#xD;
             diagnostic criteria of polycystic ovary syndrome by the Rotterdam ESHRE/ASRM-Sponsored&#xD;
             PCOS Consensus Workshop Group - by the presence of two of the following three&#xD;
             diagnostic features:&#xD;
&#xD;
               1. Oligo- or anovulation [defined as fewer than eight episodes of menstrual bleeding&#xD;
                  per year or menses that occur at intervals greater than 35 days].&#xD;
&#xD;
               2. Clinical hyperandrogenism [defined by the presence of hirsutism (assessed by a&#xD;
                  modified Ferriman-Gallwey score ≥ 8), acne or androgenic alopecia] and/or&#xD;
                  biochemical signs of hyperandrogenism [defined by elevated free androgen index]&#xD;
&#xD;
               3. Polycystic ovaries [defined as presence of 12 or more follicles in each ovary&#xD;
                  measuring 2 - 9 mm in diameter, and/or increased ovarian volume &gt; 10 mL) in the&#xD;
                  early follicular phase (cycle days 3 - 5) in regularly menstruating women.&#xD;
                  Oligo-/amenorrhoeic women should be scanned either at random or between days 3&#xD;
                  and 5 after a progestin-induced withdrawal bleeding. This definition does not&#xD;
                  apply to women taking oral contraceptive pills, since their use modifies ovarian&#xD;
                  morphology in normal women and putatively in women with PCO.&#xD;
&#xD;
             After exclusion of other etiologies (congenital adrenal hyperplasia, androgen&#xD;
             secreting tumors, Cushing's syndrome, hypothyroidism and hyperprolactinemia).&#xD;
&#xD;
          4. Normal transvaginal ultrasonography apart from polycystic ovaries (see before).&#xD;
&#xD;
          5. Normal office hysteroscopy.&#xD;
&#xD;
          6. Normal hysterosalpingography.&#xD;
&#xD;
          7. Absence of any structural pathological findings in laparoscopy apart from enlarged&#xD;
             sclerotic polycystic ovaries.&#xD;
&#xD;
          8. Normal hormonal profile (apart from hormonal abnormalities associated with PCOS), e.g.&#xD;
             normal thyroid function tests&#xD;
&#xD;
          9. Normal parameters of male semen analysis according to WHO criteria 2010.&#xD;
&#xD;
         10. First trial IVF/ICSI.&#xD;
&#xD;
         11. Written and signed informed consent by the patient to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age more than 39 years.&#xD;
&#xD;
          2. BMI more than 29 Kg/m2&#xD;
&#xD;
          3. Abnormal ultrasonographic finding, e.g. endometrial polyps, fibroids or ovarian cysts.&#xD;
&#xD;
          4. Abnormal hysteroscopic finding, e.g. endometrial polyps, endometrial hyperplasia or&#xD;
             fibroid.&#xD;
&#xD;
          5. Abnormal hysterosalpingographic finding, e.g. hydrosalpinx or peritoneal adhesions.&#xD;
&#xD;
          6. Abnormal male or female karyotyping.&#xD;
&#xD;
          7. Abnormal endocrinological profile during ovarian stimulation not attributed to PCOS,&#xD;
             e.g. hypothyroidism, FSH &gt; 12 mIU/mL on day 3.&#xD;
&#xD;
          8. Previous trials of IVF/ICSI.&#xD;
&#xD;
          9. Positive anticardiolipin antibodies or lupus anticoagulant.&#xD;
&#xD;
         10. Positive thrombophilia screen.&#xD;
&#xD;
         11. Abnormal semen analysis parameters according to WHO criteria 2010.&#xD;
&#xD;
         12. Any hormonal treatment within the last 3 months.&#xD;
&#xD;
         13. Any treatment for insulin resistance within the last 3 months, e.g. metformin or&#xD;
             leptin.&#xD;
&#xD;
         14. Any chronic medical disorder, e.g. hypertension, autoimmune disorders, … etc.&#xD;
&#xD;
         15. Any category 4 medical condition that contraindicates the usage of OCP according to&#xD;
             the WHO Medical eligibility criteria, 2015:&#xD;
&#xD;
               -  Smoking with age ≥ 35 years and cigarettes ≥ 15 /day.&#xD;
&#xD;
               -  Hypertension (systolic ≥ 160 mmHg or diastolic ≥ 90 mmHg).&#xD;
&#xD;
               -  Hypertension with vascular disease.&#xD;
&#xD;
               -  Previous history or acute DVT/PE.&#xD;
&#xD;
               -  Any known thrombogenic mutations.&#xD;
&#xD;
               -  Complicated valvular heart disease.&#xD;
&#xD;
               -  Systemic lupus erythematosus with positive or unkown antiphospholipid antibodies.&#xD;
&#xD;
               -  Migraine with aura.&#xD;
&#xD;
               -  Diabetes with nephropathy/neuropathy/retinopathy.&#xD;
&#xD;
               -  Diabetes &gt; 20 years.&#xD;
&#xD;
               -  Acute hepatitis, severe cirrhosis or liver tumors.&#xD;
&#xD;
         16. Mental condition rendering the patients unable to understand the nature, scope and&#xD;
             possible consequences of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mostafa Fouad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Abbas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khaled Afifi, MSc</last_name>
    <phone>01009981222</phone>
    <email>DrKhaledAfifi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AinShams Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khaled Afifi, MSc</last_name>
      <phone>01009981222</phone>
      <email>DrKhaledAfifi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Khaled Afifi</investigator_full_name>
    <investigator_title>Assistant lecturer of O&amp;G</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>Anatgonist protocol</keyword>
  <keyword>OCP pretreatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Gestodene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

